Literature DB >> 7830069

Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits.

L M Bierer1, V Haroutunian, S Gabriel, P J Knott, L S Carlin, D P Purohit, D P Perl, J Schmeidler, P Kanof, K L Davis.   

Abstract

Cholinergic markers, neuropeptides, and amines and their metabolites were sampled from identical specimens across 10 neocortical regions in a large sample of Alzheimer's disease (AD) cases and controls. Levels of choline acetyltransferase, acetylcholinesterase, somatostatin, corticotropin-releasing factor, serotonin, and 5-hydroxyindoleacetic acid were significantly reduced in AD versus controls. After data reduction, the most descriptive neurochemical indices were used to examine the relationship of neurochemical measures and dementia severity within the AD sample, controlling for age effects. Dementia severity ratings were based on antemortem assessments (46.9% of AD sample) and postmortem chart review (53.1% of the AD sample). Choline acetyltransferase activity was highly correlated with clinical dementia ratings across the neocortex of the AD cases. Somatostatin and corticotropin-releasing factor levels were correlated with dementia severity only when control cases were included in the analyses. None of the amines, their metabolites, or the neuropeptides quantified related significantly to dementia severity in the AD cohort. These data (a) confirm the strong association of cholinergic deficits with functional impairment in AD and show that this association is independent of age and (b) suggest that of all the neurochemical species quantified, the cholinergic indices may be unique in their association with dementia severity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7830069     DOI: 10.1046/j.1471-4159.1995.64020749.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  121 in total

1.  Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos.

Authors:  V C Hinz; S Grewig; B H Schmidt
Journal:  Neurochem Res       Date:  1996-03       Impact factor: 3.996

2.  Metrifonate and dichlorvos: effects of a single oral administration on cholinesterase activity in rat brain and blood.

Authors:  V Hinz; S Grewig; B H Schmidt
Journal:  Neurochem Res       Date:  1996-03       Impact factor: 3.996

3.  Sequence variation in the CHAT locus shows no association with late-onset Alzheimer's disease.

Authors:  Denise Harold; Timothy Peirce; Valentina Moskvina; Amanda Myers; Susan Jones; Paul Hollingworth; Pamela Moore; Simon Lovestone; John Powell; Catherine Foy; Nicola Archer; Sarah Walter; Amanda Edmonson; Stephen McIlroy; David Craig; Peter A Passmore; Alison Goate; John Hardy; Michael O'Donovan; Julie Williams; Malcolm Liddell; Michael J Owen; Lesley Jones
Journal:  Hum Genet       Date:  2003-05-21       Impact factor: 4.132

4.  Neurogenesis in Alzheimer´s disease: a realistic alternative to neuronal degeneration?

Authors:  Rocío E Gonzalez-Castaneda; Alma Y Galvez-Contreras; Sonia Luquín; Oscar Gonzalez-Perez
Journal:  Curr Signal Transduct Ther       Date:  2011-09-01

5.  Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.

Authors:  Laurel Vana; Nicholas M Kanaan; Isabella C Ugwu; Joanne Wuu; Elliott J Mufson; Lester I Binder
Journal:  Am J Pathol       Date:  2011-09-23       Impact factor: 4.307

Review 6.  Single cell gene expression profiling in Alzheimer's disease.

Authors:  Stephen D Ginsberg; Shaoli Che; Scott E Counts; Elliott J Mufson
Journal:  NeuroRx       Date:  2006-07

7.  Can zebrafish be used as animal model to study Alzheimer's disease?

Authors:  Soraya Santana; Eduardo P Rico; Javier S Burgos
Journal:  Am J Neurodegener Dis       Date:  2012-05-15

8.  CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  Hippocampus       Date:  2018-02-12       Impact factor: 3.899

9.  In vivo investigations on the cholinesterase-inhibiting effects of tricyclic quinazolinimines: scopolamine-induced cognitive impairments in rats are attenuated at low dosage and reinforced at higher dosage.

Authors:  D Appenroth; M Decker; C Tränkle; K Mohr; J Lehmann; C Fleck
Journal:  Pflugers Arch       Date:  2007-08-24       Impact factor: 3.657

10.  Serum Markers of Neurodegeneration in Maple Syrup Urine Disease.

Authors:  Giselli Scaini; Tássia Tonon; Carolina F Moura de Souza; Patricia F Schuk; Gustavo C Ferreira; Joao Seda Neto; Tatiana Amorin; Ida Vanessa D Schwartz; Emilio L Streck
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.